No Data
No Data
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Changes in Hong Kong stocks | Jinxin Reproduction (01951.HK) rose more than 6% to include assisted reproduction in many places as health insurance companies to expand the assisted reproduction market in Southeast Asia
Jinxin Reproduction (01951.HK) rose more than 6%. As of press release, it rose 6.17% to HK$2.58, with a turnover of HK$29.36,500.
Jinxin Reproduction (1951.HK) 2023 Report Review: The 23-year performance is in line with expectations and is expected to usher in a recovery in 24
Event: The company announced its annual results for '23, achieving annual revenue of 2,789 million yuan, up 18.0% year on year; realized net profit of 347 million yuan, up 194.2% year on year; adjusted net profit of 472 million yuan
Express News | Jinxin Reproduction expands the layout of the assisted reproduction market in Southeast Asia
Jinxin Reproduction (01951.HK) and Indonesia's Morula reached an equity strategic investment cooperation to expand the assisted reproduction market in Southeast Asia
On April 1, 2024, Jinxin Reproductive Medicine Group Co., Ltd. (01951.HK) announced the signing of an equity investment agreement with Indonesia's PT Morula Indonesia (“Morula”). After the investment is completed, Jinxin Fertility will become Morula's largest strategic investor. At the same time, the two sides will reach strategic cooperation, achieve resource integration, and jointly explore the assisted reproduction industry market in Indonesia and Southeast Asia. The population of Southeast Asia is huge and continues to grow. At the same time, with economic development, residents' consumption capacity is also increasing, and the assisted reproduction industry has great potential for growth.
Jinxin Reproduction (01951.HK) Hong Kong Stock Company Information Update Report: Fast recovery in 2023, the new Shenzhen campus is expected to be put into operation in 2025
Performance recovered rapidly in 2023, profitability continued to increase, maintaining the publication of the 2023 annual report by the “buy” rating company. In 2023, the company achieved revenue of 2,789 billion yuan (+18% compared to the same period, the following are all year-on-year ratios).
No Data